ABSTRACT
Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in patients with advanced non-small cell lung cancer. Up to now, neoadjuvant therapy using ICI are rare. However, in the context of cancer immunotherapy, neoadjuvant treatment may offer an extra advantage. In this review, we will disscuss the existing preclinical data and emerging clinical findings in the neoadjuvant setting and its potential mechanism of action. We will also highlight the potential damage and the questions that are required to be answered.
ABSTRACT
Objective To explore the clinical efficacy of cisplatin intraperitoneal perfusion combined with intravenous chemotherapy in the treatment of advanced gastric cancer.Methods 82 cases of patients with advanced gastric cancer were divided into two groups according to the random number table method: 41 cases of observation group were given cisplatin intraperitoneal perfusion combined with intravenous chemotherapy,41 cases in the control group received intravenous chemotherapy alone.To observe the short-term curative effect and adverse reaction.Results The total efficiency of treatment group were 46.35％(19/41)and the control group 26.83％(11/41),difference between the two groups was statistically significant(P< 0.05); the adverse reactions of the two groups of patients occurrence had no significant difference.Compared with the control group,the IgA and IgG in the observation group were significantly higher than that in the control group after treatment,the difference was significant(P<0.05); there was no significant difference between the IgM group and the control group before and after treatment.Conclusion Intraperitoneal perfusion combined with intravenous chemotherapy in patients with advanced gastric cancer can significantly improve the treatment effect,without increasing adverse reactions,it is worth popularizing.